The DEA Just Opened a Portal for Cannabis Dispensaries to Register Federally. Most Have No Idea What to Do Next.

Sometime around 9 a.m. on April 29, a federal portal went live that nobody in the cannabis industry had ever expected to see.

The Drug Enforcement Administration launched an online registration system allowing state-licensed medical marijuana dispensaries to apply for federal recognition as handlers of Schedule III controlled substances. After more than a decade of cannabis businesses operating in explicit defiance of federal law — tolerated, perhaps, but never acknowledged — the DEA was inviting them to register.

The announcement was barely a week after the Department of Justice issued its sweeping April 23 order rescheduling state-licensed medical cannabis from Schedule I to Schedule III of the Controlled Substances Act. That order was itself the culmination of a years-long rescheduling process that had been launched, stalled, litigated, and postponed so many times that the cannabis industry had largely stopped expecting it to happen.

And yet: here is the portal.

What nobody can quite agree on is what happens after you apply.

What the DEA Actually Did

The registration portal is part of a broader burst of regulatory activity the DEA published on April 28 in the Federal Register. The agency issued three separate notices in a single day.

The first addressed the mechanics of licensing for businesses that want to handle medical marijuana as a Schedule III substance — including requirements for state-licensed dispensaries to register using their existing state credentials. The second formally withdrew the DEA’s original rescheduling proposal from May 2024, which had opened a public comment period and generated more than 40,000 responses before being superseded by the DOJ’s direct order. The third scheduled an administrative hearing on whether non-medical marijuana should remain on Schedule I.

That last point is the one that tends to get lost in the news cycle: the DOJ’s rescheduling order applies specifically to state-licensed medical cannabis products. Adult-use, recreational-market cannabis — sold in Colorado, California, Oregon, Michigan, and dozens of other states — remains federally classified as Schedule I. The hearing, set to begin June 29 and run through July 15, is where that question will be formally contested.

The Confusion That’s Already Setting In

For dispensary operators trying to understand what this all means practically, the picture is murky.

Most medical cannabis states have dual-use dispensaries that serve both medical patients and adult recreational customers under the same roof. Under the current rescheduling structure, the same employee who sells a medical patient a THC tincture covered by the new federal rules might, minutes later, sell an adult recreational customer a product that remains Schedule I. Does the operator need separate federal registrations for those activities? Does one transaction type contaminate the other in the DEA’s view?

The DEA has indicated that guidance will address how businesses with “multiple activities” are treated — an acknowledgment that the medical-only framing of the rescheduling order creates serious operational ambiguity for most real-world cannabis businesses.

Treasury and the IRS added their own layer of complexity on April 24, announcing that 280E tax guidance is forthcoming but providing no timeline. The two-sentence “guidance is coming” assurance is welcome but doesn’t resolve the immediate question operators face: do they change their tax treatment now, or wait for formal rules?

“This is an already complex process made more confusing by the piecemeal nature of the administration’s approach,” one cannabis attorney told The Guardian. The partial-rescheduling structure creates situations that federal law simply wasn’t designed to handle.

Who’s Actually Helped Right Now

The clearest immediate beneficiaries of the rescheduling order are dispensaries that operate exclusively in the medical space — true medical-only programs, without an adult-use component.

For those operators, the path forward is relatively legible: register with the DEA using existing state credentials, wait for Treasury guidance on 280E before altering tax filings, and begin preparing for FDA oversight frameworks that will presumably follow at some point. The financial upside is real. Medical cannabis businesses have been paying effective federal tax rates of 50 to 70 percent or higher under 280E’s restrictions. Even partial relief would materially improve margins.

The harder story is the majority of the industry — operators in dual-use states, multi-state operators with both medical and recreational revenue streams, and the countless dispensaries that have built their businesses on the assumption that federal legalization, if it came, would come all at once rather than in a carefully carved medical-only slice.

The June Hearing and What It Means

The DEA’s scheduling of an administrative hearing on non-medical marijuana’s Schedule I status is a significant procedural step, even if the outcome is uncertain.

Anyone who wants to participate — including cannabis companies, advocacy groups, researchers, or individual citizens — must file a participation request with the DEA by May 28. The agency will notify selected participants by June 22. Acting Attorney General Todd Blanche will designate an administrative law judge to preside, though that appointment had not yet been made as of the Federal Register publication.

Administrative hearings in DEA rescheduling proceedings are formal, adversarial processes. The hearing scheduled for January 2025 — which was postponed — already had dozens of parties lined up to participate. The June hearing will likely draw a similar field.

For the industry, what matters is what the hearing process signals about timeline. Even if the June hearing proceeds on schedule, any resulting rule change would require additional notice-and-comment rulemaking before taking effect. A realistic path to full cannabis rescheduling — or descheduling — through this administrative process probably doesn’t resolve before 2027 at the earliest.

Where Things Actually Stand

The portal is live. The hearing is scheduled. The guidance is forthcoming.

What exists right now is a federal government that has taken its clearest step yet toward treating cannabis as something other than a fully illegal substance — while simultaneously hedging that step with every procedural and definitional qualifier available. Medical, not recreational. Schedule III, not descheduled. Guidance expected, not issued. Applications accepted, terms TBD.

For the patients in strict medical states who have never had access to adult-use cannabis and who’ve watched rescheduling debates drag on for years, the moment still represents something real: the federal government is, for the first time, formally acknowledging the existence of their dispensaries.

For the broader industry, the wait continues. The DEA’s portal is open. The questions are still piling up faster than the answers.

Maya Torres covers national cannabis news and federal policy for CannabisInquirer.com. She is based in Washington, D.C.